Ranbaxy (UK) Limited (RUKL)

The UK subsidiary Ranbaxy (UK) Limited (RUKL), recorded a sales turnover of US$ 15.3 million, an impressive growth of 27% over the previous year, and moved up to join the top-ten players in the British generics market. By working actively and aggressively, Ranbaxy broadened both its product and customer-base through a series of supply agreements and strategic tie-ups. Consequently, Ranbaxy’s

Activity:

Product / Technology type(s) covered:

- Generics
- Pharmaceuticals / Therapeutics

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active: Europe

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: